---
title: "Biodexa to issue Series M, N and O warrants with $2.85 exercise price pending shareholder approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291279347.md"
description: "Biodexa priced a $3.5 million financing involving pre-funded warrants, new warrants, and inducement warrants. To encourage immediate cash exercise of existing warrants, the company agreed to reduce their exercise price to USD 2.85. Pending shareholder approval, Biodexa will issue Series M, N, and O unregistered warrants for a total of approximately 2.2 million ADSs, all carrying the reduced USD 2.85 exercise price and expiring five years post-approval."
datetime: "2026-06-30T12:03:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291279347.md)
  - [en](https://longbridge.com/en/news/291279347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291279347.md)
---

# Biodexa to issue Series M, N and O warrants with $2.85 exercise price pending shareholder approval

-   Biodexa priced a $3.5 million financing featuring pre-funded warrants, new warrants, and a warrant inducement tied to cash exercise of existing warrants. \* Company agreed to cut the exercise price on existing warrants to USD 2.85 to induce immediate cash exercise. \* Subject to shareholder approval, Biodexa will issue unregistered Series O warrants for 1,219,512 ADSs; Series M warrants for 282,952 ADSs; Series N warrants for 701,754 ADSs. \* All new warrants carry a USD 2.85 exercise price, become exercisable only after shareholder approval, and expire five years after approval. \* Biodexa also plans to file SEC registration statement(s) covering resale of ADSs issuable on exercise of the pre-funded warrants and warrants. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED1001210364) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BDRX.US](https://longbridge.com/en/quote/BDRX.US.md)

## Related News & Research

- [Biodexa prices $1 million private placement of pre-funded warrants at $2.85 per ADS](https://longbridge.com/en/news/291284733.md)
- [Biodexa seeks shareholder approval to adopt new articles of association for E deferred shares](https://longbridge.com/en/news/292238558.md)
- [BIO-key enters deal for investor to exercise warrants at USD 4.06 per share, raising USD 2.5 million](https://longbridge.com/en/news/295537205.md)
- [Femasys prices USD 30 million private placement at USD 3.2 per share](https://longbridge.com/en/news/295242055.md)
- [Lakewood-Amedex Biotherapeutics announces annual shareholder meeting](https://longbridge.com/en/news/295452742.md)